Skip to main content

Ginkgo Bioworks Holdings (DNA) Receives a Buy from TD Cowen

Tipranks - Tipranks - Sat Jul 19, 2025

In a report released today, Brendan Smith from TD Cowen maintained a Buy rating on Ginkgo Bioworks Holdings, with a price target of $12.00. The company’s shares closed yesterday at $9.76.

Elevate Your Investing Strategy:

Smith covers the Healthcare sector, focusing on stocks such as Halozyme, Azenta, and Codexis. According to TipRanks, Smith has an average return of -1.4% and a 36.27% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Ginkgo Bioworks Holdings with a $9.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Ginkgo Bioworks Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $48.32 million and a GAAP net loss of $90.96 million. In comparison, last year the company earned a revenue of $37.94 million and had a GAAP net loss of $165.91 million

Read More on DNA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).